ClinConnect ClinConnect Logo
Search / Trial NCT06432127

Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis

Launched by MAHIDOL UNIVERSITY · May 21, 2024

Trial Information

Current as of July 02, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether an injection called a greater occipital nerve block, performed under ultrasound guidance, can help prevent migraines in people who haven’t had success with oral medications. The researchers want to see if injecting a local anesthetic at the back of the head can reduce the frequency and severity of migraine attacks for those who experience them frequently or have chronic migraines.

To be eligible for the study, participants need to be between 18 and 65 years old, have a diagnosis of either episodic or chronic migraines, and have tried other migraine treatments without satisfactory results. The trial will involve two groups: one receiving the anesthetic and the other receiving a saline solution (a placebo). Participants can expect to have their headaches monitored over several weeks, and they will complete questionnaires to assess how their migraines affect their daily lives. It’s important to note that the trial is not yet recruiting participants, so interested individuals will need to wait until recruitment begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 18 -65 years old
  • 2. Diagnosis as episodic migraine or chronic migraine and had indication to use migraine prophylaxis
  • 3. Volunteer prefer to use research procedure as first choice of migraine prophylaxis
  • 4. Volunteer already had migraine prophylaxis treatment but still has the one of these following problem 4.1 Frequency of migraine attack more than 4 times/month 4.2 Severe migraine headache \& disturb daily life in spite of using migraine prophylaxis 4.3 Having migraine medication side effect, either from prophylaxis or acute attack medication and cannot titration medication dosage 4.4 migraine attack not improved as using many migraine prophylaxis medications 4.5 Having contra-indication to use prophylaxis migraine medication or standard prophylaxis procedure such as botulinum toxin 4.6 Cannot take prophylaxis medication daily (low compliance) 4.7 Had financial problems in using standard prophylaxis migraine medication or procedure 4.8 Medication overuse headache
  • Exclusion Criteria:
  • 1. Had these type of headache in combination with migraine
  • cervicogenic headache
  • occipital neuralgia
  • secondary headache
  • 2. Had contraindication on greater occipital nerve block injection at cervical spine level 2 under ultrasound-guided such as skin infection in needle site
  • 3. Allergy to local anesthetic
  • 4. Uncontrolled psychiatric disorder in 3 months before attending research
  • 5. Cannot understand or reading, writing Thai language

About Mahidol University

Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.

Locations

Bangkok, , Thailand

Patients applied

0 patients applied

Trial Officials

RAVIWON ATISOOK, M.D.

Principal Investigator

Siriraj Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported